| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $4,800,000 | 1 | 2 |
Sells | $9,115,658 | 41 | 98 |
| RA CAPITAL MANAGEMENT, L.P. | 1 | $4.8M | 0 | $0 | $4.8M | |
| Raben David | Chief Medical Officer | 0 | $0 | 6 | $654,216 | $-654,216 |
| Mazumdar Claire | Chief Executive Officer | 0 | $0 | 11 | $2.43M | $-2.43M |
| Hyep Ivan | Chief Financial Officer | 0 | $0 | 11 | $2.57M | $-2.57M |
| Cohlhepp Ryan | President and COO | 0 | $0 | 13 | $3.46M | $-3.46M |
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara …
Over the last 12 months, insiders at Bicara Therapeutics Inc. Common Stock have bought $4.8M and sold $9.12M worth of Bicara Therapeutics Inc. Common Stock stock.
On average, over the past 5 years, insiders at Bicara Therapeutics Inc. Common Stock have bought $19.21M and sold $6.83M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $4.8M.
The last purchase of 300,000 shares for transaction amount of $4.8M was made by RA CAPITAL MANAGEMENT, L.P. () on 2026‑02‑26.
| 2026-09-08 | Sale | Cohlhepp Ryan | President, COO & Interim CEO | 17,500 0.0249% | $22.90 | $400,716 | -25.66% | |
| 2026-08-10 | Sale | Mazumdar Claire | Chief Executive Officer | 10,000 0.0166% | $27.98 | $279,750 | -23.40% | |
| 2026-08-10 | Sale | Cohlhepp Ryan | President and COO | 18,750 0.0312% | $27.98 | $524,533 | -23.40% | |
| 2026-08-10 | Sale | Hyep Ivan | Chief Financial Officer | 12,500 0.0208% | $27.97 | $349,591 | -23.40% | |
| 2026-07-10 | Sale | Mazumdar Claire | Chief Executive Officer | 10,000 0.0179% | $28.42 | $284,198 | -19.75% | |
| 2026-07-09 | Sale | Cohlhepp Ryan | President and COO | 536 0.001% | $29.00 | $15,544 | -21.60% | |
| 2026-07-08 | Sale | Cohlhepp Ryan | President and COO | 28,214 0.0515% | $28.98 | $817,585 | -19.49% | |
| 2026-07-08 | Sale | Hyep Ivan | Chief Financial Officer | 28,000 0.0509% | $28.85 | $807,672 | -19.49% | |
| 2026-05-21 | Sale | Hyep Ivan | Chief Financial Officer | 9,200 0.0165% | $20.42 | $187,883 | +11.06% | |
| 2026-05-18 | Sale | Mazumdar Claire | Chief Executive Officer | 15,000 0.0284% | $20.04 | $300,579 | +19.75% | |
| 2026-05-15 | Sale | Cohlhepp Ryan | President and COO | 12,500 0.0229% | $20.29 | $253,649 | +13.74% | |
| 2026-04-27 | Sale | Raben David | Chief Medical Officer | 5,500 0.0102% | $22.88 | $125,830 | +1.20% | |
| 2026-04-21 | Sale | Hyep Ivan | Chief Financial Officer | 9,200 0.0167% | $23.00 | $211,614 | -1.56% | |
| 2026-04-20 | Sale | Mazumdar Claire | Chief Executive Officer | 15,000 0.0269% | $23.61 | $354,146 | -2.94% | |
| 2026-04-15 | Sale | Cohlhepp Ryan | President and COO | 12,500 0.0221% | $23.01 | $287,591 | -3.77% | |
| 2026-03-25 | Sale | Raben David | Chief Medical Officer | 5,500 0.0102% | $18.95 | $104,229 | +21.23% | |
| 2026-03-23 | Sale | Hyep Ivan | Chief Financial Officer | 9,200 0.0169% | $18.52 | $170,348 | +22.97% | |
| 2026-03-20 | Sale | Mazumdar Claire | Chief Executive Officer | 1,596 0.003% | $18.95 | $30,246 | +22.71% | |
| 2026-03-19 | Sale | Mazumdar Claire | Chief Executive Officer | 6,905 0.0126% | $18.78 | $129,705 | +20.20% | |
| 2026-03-18 | Sale | Mazumdar Claire | Chief Executive Officer | 6,499 0.0121% | $18.84 | $122,415 | +22.65% |
| RA CAPITAL MANAGEMENT, L.P. | 4603418 6.9566% | $41.25M | 2 | 0 | <0.0001% | |
| Flynn James E | Possible Members of 10% Group | 897587 1.3564% | $8.04M | 1 | 0 | <0.0001% |
$10,154,205 | 103 | -4.60% | $631.34M | |
$860,541,348 | 82 | -5.10% | $649.64M | |
$40,226,318 | 58 | 18.89% | $539.26M | |
$16,169,789 | 40 | 7.44% | $485.1M | |
$1,344,238 | 38 | 23.07% | $639.18M |
| Increased Positions | 90 | +74.38% | 13M | +25.92% |
| Decreased Positions | 53 | -43.8% | 6M | -12.51% |
| New Positions | 45 | New | 7M | New |
| Sold Out Positions | 18 | Sold Out | 3M | Sold Out |
| Total Postitions | 158 | +30.58% | 57M | +13.41% |
| Ra Capital Management, L.P. | $113,939.00 | 12.65% | 6.96M | 0 | 0% | 2025-09-30 |
| Siren, L.L.C. | $85,454.00 | 9.49% | 5.22M | 0 | 0% | 2025-09-30 |
| Vestal Point Capital, Lp | $83,538.00 | 9.27% | 5.1M | +100,000 | +2% | 2025-09-30 |
| Red Tree Management, Llc | $51,933.00 | 5.77% | 3.17M | 0 | 0% | 2025-09-30 |
| Tpg Gp A, Llc | $49,311.00 | 5.47% | 3.01M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $44,199.00 | 4.91% | 2.7M | +159,957 | +6.3% | 2025-09-30 |
| Deep Track Capital, Lp | $39,749.00 | 4.41% | 2.43M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $37,867.00 | 4.2% | 2.31M | +200,469 | +9.49% | 2025-09-30 |
| Omega Fund Management, Llc | $36,112.00 | 4.01% | 2.2M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $36,051.00 | 4% | 2.2M | +195,667 | +9.76% | 2025-09-30 |